Immunosuppressive Drugs Companies

Pfizer (US) announces positive phase 3 trial results for its investigational IL-23 inhibitor etrasimod for the treatment of moderate-to-severe ulcerative colitis.

Roche (Switzerland) receives FDA approval for Actemra (tocilizumab) for the treatment of macrophage activation syndrome (MAS) in children and adults.

Bristol Myers Squibb (US) and Takeda Pharmaceutical Company Limited (Japan) collaborate to develop and commercialize a novel anti-CD40 monoclonal antibody for the treatment of autoimmune diseases.

Novartis (Switzerland) acquires Gyroscope Therapeutics Inc. (US) for USD 800 million, gaining access to GT004, a potential best-in-class IL-17A inhibitor for various autoimmune diseases.

Sanofi (France) expands its portfolio of immunosuppressive drugs with the acquisition of Amun Therapeutics Inc. (US), gaining access to a pipeline of novel immune-tolerizing therapies.

• Accord Healthcare (UK)


• Astella Pharma (Japan)


• Bristol-Myers Squibb Company (US)


• Genzyme Co. (Switzerland)


• Hoffmann-La Roche AG (US


• GlaxoSmithKline PLC (UK)


• Glenmark Pharmaceuticals, Inc. (India)


• Mylan Laboratories Inc. (US)


• Pfizer Inc. (US)


• Novartis AG (Switzerland)


• Actavis, Inc.